The previously mentioned findings were independent of the simultaneous treatment with CTLA-4 inhibitors, indicating that the sole blockade of PD-1 may be sufficient to enhance immune function and for treatment of melanoma [25]. This evidence concerns the gene CTLA4 and melanoma.